Pular para o conteúdo
Merck
Todas as fotos(1)

Documentos Principais

SML0327

Sigma-Aldrich

AM630

≥90% (HPLC)

Sinônimo(s):

6-Iodo-2-methyl-1-[2-(4-morpholinyl)ethyl]-1H-indol-3-yl](4-methoxyphenyl)methanone, AM 630, Iodopravadoline

Faça loginpara ver os preços organizacionais e de contrato


About This Item

Fórmula empírica (Notação de Hill):
C23H25IN2O3
Número CAS:
Peso molecular:
504.36
Número MDL:
Código UNSPSC:
12352200
ID de substância PubChem:
NACRES:
NA.77
Preço e disponibilidade não estão disponíveis no momento.

Ensaio

≥90% (HPLC)

Formulário

powder

condição de armazenamento

desiccated

cor

white to beige

solubilidade

DMSO: >5 mg/mL

temperatura de armazenamento

2-8°C

cadeia de caracteres SMILES

COc1ccc(cc1)C(=O)c2c(C)n(CCN3CCOCC3)c4cc(I)ccc24

InChI

1S/C23H25IN2O3/c1-16-22(23(27)17-3-6-19(28-2)7-4-17)20-8-5-18(24)15-21(20)26(16)10-9-25-11-13-29-14-12-25/h3-8,15H,9-14H2,1-2H3

chave InChI

JHOTYHDSLIUKCJ-UHFFFAOYSA-N

Aplicação

AM630 has been used:
  • as a cannabinoid 2(CB2) inhibitor to study the analgesic effect exerted by polysaccharopeptide from Trametes versicolor (TPSP).[1]
  • as a CB2 antagonist along with β-caryophyllene (BCP) to study its effects on re-epithilialization of fibroblast cells.[2]
  • as a CB2 antagonist to study its interaction with 17-β-estradiol in primary human osteoblasts.[3]

Ações bioquímicas/fisiológicas

AM630 is a selective CB2 cannabinoid antagonist/inverse agonist (Ki = 31.2 nM) with > 150-fold selectivity over CB1 receptors.
AM630 is a selective CB2 cannabinoid antagonist/inverse agonist.
AM630 is an aminoalkylindole and acts as a competitive antagonist of CP 55,940 and WIN 55,212-2. It also behaves as a competitive antagonist of anandamide and (R)-(+)-arachidonyl-1′-hydroxy-2′-propylamide (AM356).[4]

Características e benefícios

This compound is featured on the Cannabinoid Receptors page of the Handbook of Receptor Classification and Signal Transduction. To browse other handbook pages, click here.

Pictogramas

Environment

Palavra indicadora

Warning

Frases de perigo

Declarações de precaução

Classificações de perigo

Aquatic Acute 1 - Aquatic Chronic 1

Código de classe de armazenamento

11 - Combustible Solids

Classe de risco de água (WGK)

WGK 3

Ponto de fulgor (°F)

Not applicable

Ponto de fulgor (°C)

Not applicable


Escolha uma das versões mais recentes:

Certificados de análise (COA)

Lot/Batch Number

Não está vendo a versão correta?

Se precisar de uma versão específica, você pode procurar um certificado específico pelo número do lote ou da remessa.

Já possui este produto?

Encontre a documentação dos produtos que você adquiriu recentemente na biblioteca de documentos.

Visite a Biblioteca de Documentos

Os clientes também visualizaram

Sachiko Koyama et al.
PloS one, 14(12), e0216104-e0216104 (2019-12-17)
Beta-caryophyllene is an odoriferous bicyclic sesquiterpene found in various herbs and spices. Recently, it was found that beta-caryophyllene is a ligand of the cannabinoid receptor 2 (CB2). Activation of CB2 will decrease pain, a major signal for inflammatory responses. We
Massimo Nabissi et al.
Oncotarget, 7(47), 77543-77557 (2016-10-22)
Several studies showed a potential anti-tumor role for cannabinoids, by modulating cell signaling pathways involved in cancer cell proliferation, chemo-resistance and migration. Cannabidiol (CBD) was previously noted in multiple myeloma (MM), both alone and in synergy with the proteasome inhibitor
R Pertwee et al.
Life sciences, 56(23-24), 1949-1955 (1995-01-01)
AM630 (iodopravadoline), a novel aminoalkylindole, has been found to attenuate the ability of a number of cannabinoids to inhibit electrically-evoked twitches of the mouse isolated vas deferens. It did not block the inhibitory effects of morphine or clonidine on the
Marko Hojnik et al.
Biomedical reports, 3(4), 554-558 (2015-07-15)
The bone remodeling process is influenced by various factors, including estrogens and transmitters of the endocannabinoid system. In osteoblasts, cannabinoid receptors 2 (CB-2) are expressed at a much higher level compared to CB-1 receptors. Previous studies have shown that estrogens
K A Jenkin et al.
British journal of pharmacology, 173(7), 1128-1142 (2014-12-30)
In diabetic nephropathy agonism of CB2 receptors reduces albuminuria and podocyte loss; however, the role of CB2 receptors in obesity-related nephropathy is unknown. The aim of this study was to determine the role of CB2 receptors in a model of

Questions

Reviews

No rating value

Active Filters

Nossa equipe de cientistas tem experiência em todas as áreas de pesquisa, incluindo Life Sciences, ciência de materiais, síntese química, cromatografia, química analítica e muitas outras.

Entre em contato com a assistência técnica